

**NAPROXEN- naproxen tablet**  
**Alivio Medical Products, LLC**

-----  
**Drug Facts**

**Each capsule contains:**

Naproxen, USP .....500 mg

**Dosage and Use:** For dosage recommendations

and other important prescribing information, read accompanying insert.

Store at 20 to 25 C (68 to 77 F); excursions

permitted to 15 to 30 C (59 to 86 F)[See

USP Controlled Room Temperature]

Dispense in well-closed, light-resistant containers

as defined in the USP.

**BOXED WARNING**

**Cardiovascular Risk**

-NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal.

-Naproxen as Naproxen Tablets, USP is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).

**Gastrointestinal Risk**

-NSAIDs may cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.

**DESCRIPTION**

Naproxen, USP is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs.

**CLINICAL PHARMACOLOGY**

Pharmacodynamics - Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties.

**CLINICAL STUDIES**

General Information - Naproxen has been studied in patients with rheumatoid arthritis, osteoarthritis, juvenile arthritis, ankylosing spondylitis, tendonitis and bursitis, and acute gout.

**INDICATIONS AND USAGE**

Carefully consider the potential benefits and risks of naproxen tablets, USP and other treatments before deciding to use naproxen tablets, USP.

**CONTRAINDICATIONS**

Naproxen tablets, USP are contraindicated in patients with known hypersensitivity to naproxen, USP.

## WARNINGS

Cardiovascular Effects - Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and non-selective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV)

thrombotic events, myocardial infarction, and stroke, which can be fatal.

## PRECAUTIONS

**General - Naproxen - containing products such as naproxen tablets, and other naproxen products should**

**not be used concomitantly since they all circulate in the plasma as the naproxin anion.**

## ADVERSE REACTIONS

Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below.

## OVERDOSAGE

Symptoms and Signs Significant naproxen overdosage may be characterized by lethargy, dizziness, drowsiness, epigastric pain, abdominal discomfort, heartburn, indigestion, nausea, transient alterations in liver function,

hypoprothrombinemia, renal dysfunction, metabolic acidosis, apnea, disorientation or vomiting.

## DOSAGE AND ADMINISTRATION

Carefully consider the potential benefits and risks of naproxen tablets, USP and other treatment options before deciding to use naproxen tablets, USP.

## MEDICATION GUIDE FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

(See the end of this Medication Guide for a list of prescription NSAID medicines.)

**NDC 69512-190-10**

**Naproxen Tablets  
USP**

**500 mg**

**Rx Only**      **100 Capsules**

**Alivio Medical Products**  
Quality you can count on.

**Each capsule contains:**  
Naproxen, USP ..... 500 mg

**Dosage and Use:** For dosage recommendations and other important prescribing information, read accompanying insert.

**Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].**

**Dispense in well-closed, light-resistant containers as defined in the USP.**

Distributed By:  
Able Wholesalers  
1329A Baptist World Center Dr.  
Nashville, TN 37207  
800-430-9814

69512-190-10

Lot No:  
Exp. Date:

naproxen tablet

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:69512-190
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
NAPROXEN (UNII: 57Y76R9ATQ) (NAPROXEN - UNII:57Y76R9ATQ)	NAPROXEN	500 mg in 500 mg

### Inactive Ingredients

<b>Ingredient Name</b>	<b>Strength</b>
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)	
POVIDONES (UNII: FZ989GH94E)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	

### Product Characteristics

<b>Color</b>	white (White)	<b>Score</b>	no score
<b>Shape</b>	CAPSULE	<b>Size</b>	16 mm
<b>Flavor</b>		<b>Imprint Code</b>	IP190;500
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69512-190-10	100 in 1 BOTTLE		
1		500 mg in 1 CAPSULE; Type 0: Not a Combination Product		

### Marketing Information

<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
ANDA	ANDA075927	10/01/2015	

**Labeler** - Alivio Medical Products, LLC (079670828)

Revised: 10/2015

Alivio Medical Products, LLC